Immunic logo
Immunic
IMUX | NASDAQ
Chart Builder DCF Calculator
$7.23
-$0.29 (-3.86%)
At close: Nov 16, 2026, 4:00 PM ET
$7.23
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

Immunic Company Profile

Company profile explained

Company Profile

Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.

Key Executives

Name Position
Erik Lundgren Chief Executive Officer & Director
Glenn Whaley Chief Financial Officer
Jason Tardio Chief Operating Officer & President
Chitrang Davé Chief Data & Digital Officer
Hella Kohlhof Co-Founder & Chief Scientific Officer
Inderpal Singh General Counsel
Jessica Breu Vice President of Investor Relations & Communications
Michael A. Panzara Chief Medical Officer
Patrick Walsh Chief Business Officer
Werner Gladdines Chief Development Officer

Latest SEC Filings

Date Type Title
Oct 01, 2026 S-8 Filing
Sep 18, 2026 4 Filing
Sep 18, 2026 4 Filing
Sep 11, 2026 8-K Current Report
Sep 09, 2026 8-K Current Report
Aug 14, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 13, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 12, 2026 S-8 Filing
View All SEC Filings ➞
Immunic
Immunic logo
Country United States
IPO Date Apr 17, 2014
Industry Biotechnology
Sector Healthcare
Employees 100
CEO Erik Lundgren

Contact Details

1200 Avenue of the Americas New York City, New York 10036 United States

Stock Details

Ticker Symbol IMUX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001280776
CUSIP Number 4525EP200
ISIN Number US4525EP2001
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.